Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$29.05M

FY 2025 · Annual

Investing Cash Flow

-$599,256.00

FY 2025 · Annual

Financing Cash Flow

$77.39M

FY 2025 · Annual

+69.0% YoY

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(23.37M)(23.26M)(28.15M)(25.74M)(38.61M)
Depreciation & Amortization111.53K200.24K117.1K235.25K241.88K
Deferred Income Tax1.2M0000
Stock-Based Compensation4.21M1.43M1.06M3.22M9.04M
Change in Working Capital(211.43K)2.07M4.76M(6.76M)(726.19K)
Accounts Receivables190.89K310.06K(105.39K)(101.39K)(439K)
Inventory0(1.32M)(435.12K)00
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(402.32K)1.76M4.87M(5.95M)(2.69M)
Other Non-Cash Items3.41M776.17K1.51M(944.03K)1M
Operating Cash Flow(14.64M)(18.78M)(21.02M)(29.99M)(29.05M)
Capital Expenditures(431.67K)(308.37K)(55.25K)(104.23K)(599.26K)
Acquisitions (Net)0310039.82K0
Purchases of Investments(9M)(310)000
Sales of Investments09.01M000
Other Investing Activities(5.02M)310027.81K0
Investing Cash Flow(14.45M)8.7M(73.2K)(75.16K)(599.26K)
Debt Repayment12.17M(97.49K)(108.75K)(9.14M)0
Common Stock Issued29.67M10.64M11.96M54.56M77.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(87.7K)(87.7K)9.11M363.06K0
Financing Cash Flow49.92M13.52M20.96M45.78M77.39M
Effect of Forex Changes(81.63K)396.83K821.4K(1.96M)(1.99M)
Net Change in Cash20.74M3.84M1.08M13.76M45.75M
Free Cash Flow(15.07M)(19.08M)(21.09M)(30.1M)(29.65M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$38.6M
+ D&A$241.9K
+ Stock-Based Comp$9.0M
+ Deferred Tax$0
- Working Capital-$726.2K
+ Other Non-Cash$1.0M
= Operating Cash Flow-$29.1M
- Capex-$599.3K
= Free Cash Flow-$29.7M

Analysis

FY2025 free cash flow is -$29.7M. FCF conversion is 76.8% of net income. Operating cash flow was -$29.1M, with capex of -$599.3K. The largest bridge item is Stock-Based Comp at $9.0M.

Recent Filings

Recent regulatory filings

No filings found.

Does EPRX.TO generate free cash flow?

Eupraxia Pharmaceuticals Inc. (EPRX.TO) generated -$29.65M of free cash flow in fiscal 2025.

How much operating cash flow does EPRX.TO produce?

Operating cash flow was -$29.05M, before capital expenditures of $599,259.00.